All Access Articles |
- Apogee Therapeutics Initiates Clinical Trial for Novel Antibody APG333 | 2024-12-10 | BIOTECHNOLOGY
- Apogee Therapeutics – Positive Phase 1 Data for APG808 Indicating Long Half-Life and Potential Dosing Flexibility | 2024-12-02 | BIOTECHNOLOGY
- Apogee Therapeutics Initiates First Clinical Trial for APG990 | 2024-08-19 | BIOTECHNOLOGY